Clinical trials
CMV clinical trials
Below are recruiting cmv clinical trials, each written for real people, not researchers. We’re tracking 60 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06066957RecruitingPhase 2
Oral letermovir to prevent CMV after heart or lung transplant
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06407232RecruitingPhase 3
Letermovir for CMV after kidney or pancreas transplant
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Madison, WisconsinAges 18 years+ - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25 - NCT06793124Recruiting
Comparing tests for CMV in bowel disease patients
This trial compares different diagnostic tests to find the best way to detect cytomegalovirus (CMV) organ disease in people with inflammatory bowel disease (IBD) whose symptoms get worse and need hospital care. The goal is to improve diagnosis and treatment for this complication.
Bologna, BolognaAges 18 years+ - NCT06853184RecruitingPhase 2
Artesunate for CMV in transplant patients
This trial tests a study drug called artesunate as a possible new treatment for CMV (a common virus) in people who have had a kidney, lung, heart, or liver transplant. It is for patients whose CMV infection requires treatment with standard antivirals like ganciclovir or valganciclovir.
Boston, MassachusettsAges 18 years+ - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT01011712Recruiting
Study immune causes of severe viral infections
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
Bethesda, MarylandAges 2–100 - NCT03159364RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests whether specially grown immune cells (T cells) can fight common viruses like CMV, EBV, or BK virus in people with weakened immune systems, such as after a stem cell or organ transplant. It may help when standard medicines don't work or can't be used.
Shenzhen, GuangdongAges 6 months–80 years - NCT07609576Recruiting
Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Madrid, MadridAges 18 years+
Hear when a new CMV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cmv?
- Yes. Clin2 currently lists 60 recruiting cmv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cmv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cmv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.